In short, through our combined focus on operational efficiency and new product innovation, we're pleased to drive 15% growth year-over-year in sales and rentals of our lymphedema products, while reducing our sales and marketing expense. Turning to our airway clearance product line, our year-over-year sales performance in the third quarter continued to be impacted by the dynamic we discussed on our earnings call in August, with one large DME customer experiencing slowed placements of our AffloVest system. As a reminder, May 11th saw the expiration of the COVID-19 public health emergency or PHE waiver and a return to pre-public health emergency eligibility requirements. This large DME customer was one of the few we partner with that took advantage of the relaxed eligibility requirements under the PHE waiver.